Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: A U.S.–Canadian multicenter study

• Published in: Journal of hepatology Vol. 47; no. 4; pp. 527 - 537
• Main Authors: Bräu, Norbert, Fox, Rena K, Xiao, Peiying, Marks, Kristen, Naqvi, Zeenat, Taylor, Lynn E, Trikha, Anita, Sherman, Morris, Sulkowski, Mark S, Dieterich, Douglas T, Rigsby, Michael O, Wright, Teresa L, Hernandez, Maria D, Jain, Mamta K, Khatri, Gajendra K, Sterling, Richard K, Bonacini, Maurizio, Martyn, Catherine A, Aytaman, Ayse, Llovet, Josep M, Brown, Sheldon T, Bini, Edmund J
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.10.2007
• Subjects: Adult; Canada; Carcinoma, Hepatocellular - diagnosis; Carcinoma, Hepatocellular - pathology; Carcinoma, Hepatocellular - therapy; Female; Gastroenterology and Hepatology; Hepatitis B; Hepatitis C; Hepatitis C, Chronic - complications; Hepatocellular Carcinoma; HIV; HIV Infections - complications; Humans; Liver Neoplasms - diagnosis; Liver Neoplasms - pathology; Liver Neoplasms - therapy; Male; Middle Aged; Neoplasm Staging; Prognosis; Treatment; Treatment Outcome; United States; Canada; United States; alfa-fetoprotein; hepatitis B virus; ESLD; highy-active antiretroviral therapy; HCC; human immunodeficiecny virus; AFP; Child-Turcotte-Pugh; end-stage liver disease; Treatment; HIV; hepatitis C virus; HCV; Hepatitis C; HBV; hepatocellular carcinoma; CTP; HAART; Hepatitis B; Hepatocellular Carcinoma
• ISSN: 0168-8278; 1600-0641
• DOI: 10.1016/j.jhep.2007.06.010

Background/Aims HIV-infected patients now live longer and often have complications of liver disease, especially with hepatitis B or C virus coinfection. Limited data are available on those with hepatocellular carcinoma (HCC). Methods A retrospective analysis from 1992 to 2005 in 6 centers identified 63 HIV-infected HCC patients. Controls were 226 consecutive HIV-negative HCC patients from four sites. Results HIV-positive patients were younger than controls (52 vs. 64 years, p < 0.001), more commonly had chronic hepatitis B or C (97% vs. 73%, p < 0.001), were more frequently symptomatic (51% vs. 38%, p = 0.048), had a higher median alfa-fetoprotein level (227 vs. 51 ng/ml, p = 0.005), but a similar mean Child–Turcotte–Pugh score (7.0 vs. 7.5, p = 0.05) and HCC staging score (Barcelona-Clínic-Liver-Cancer stages C + D in 50% vs. 58%, p = 0.24). HCC developed faster in HIV/HCV-coinfected than in HCV-monoinfected patients (mean, 26 vs. 34 years after HCV infection, p = 0.002). HIV-positive patients received proven therapy more often (48% vs. 31%, p = 0.017), but median survival was similar (6.9 vs. 7.5 months, p = 0.44). Independent factors predicting survival were symptomatic presentation (hazard ratio [HR], 0.437; p < 0.001), any proven therapy (HR, 2.19; p < 0.001), diagnosis after 01-Jan-2002 (HR, 1.52; p = 0.010), Barcelona-Clínic-Liver-Cancer stages C + D (HR, 0.491; p < 0.001), AST/ALT ⩾ 2.00 (HR, 0.597; p = 0.001), AFP ⩾ 400 ng/mL (HR, 0.55, p = 0.003), and platelets ⩾ 100,000/mm3 (HR, 0.651; p = 0.012), but not HIV-serostatus ( p = 0.19). In HIV-infected patients without HCC therapy ( n = 33), median survival was longer with undetectable HIV RNA (<400 copies/mL) than with HIV viremia (6.5 vs. 2.6 months, p = 0.013). Conclusions HIV-positive HCC patients are younger and more frequently symptomatic and infected with HCV or HBV than HIV-negative patients. Tumor staging and survival are similar. In untreated patients, undetectable HIV RNA independently predicts better survival.